The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes
暂无分享,去创建一个
D. Houitte | B. Maillère | A. Närvänen | T Virtanen | P. Sirven | A Immonen | T Kinnunen | P Sirven | A Taivainen | D Houitte | J Peräsaari | A Närvänen | S Saarelainen | M Rytkönen-Nissinen | B Maillere | T. Kinnunen | T. Virtanen | J. Peräsaari | A. Taivainen | S. Saarelainen | M. Rytkönen-Nissinen | A. Immonen | A. Närvänen
[1] J. Partanen,et al. The DR4–DQ8 haplotype and a specific T cell receptor Vβ T cell subset are associated with absence of allergy to Can f 1 , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[2] R. O’Hehir,et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.
[3] E. Sercarz,et al. How some T cells escape tolerance induction , 1989, Nature.
[4] Dexiang Chen,et al. Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models. , 2005, Vaccine.
[5] Amos Bairoch,et al. The PROSITE database, its status in 2002 , 2002, Nucleic Acids Res..
[6] D. Wraith,et al. Peptide-based therapeutic vaccines for allergic and autoimmune diseases , 2005, Nature Medicine.
[7] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[8] T. Platts-Mills,et al. Different sensitization profile for asthma, rhinitis, and eczema among 7‐8‐year‐old children: Report from the Obstructive Lung Disease in Northern Sweden studies , 2003, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[9] D R Flower,et al. The lipocalin protein family: structural and sequence overview. , 2000, Biochimica et biophysica acta.
[10] S. Atiş,et al. Sensitization to horse hair, symptoms and lung function in grooms , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[11] C. Akdis,et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.
[12] R. Aalberse,et al. The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms , 1997, Immunology.
[13] R. Simon,et al. Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis , 2004, The Journal of Immunology.
[14] R. Wood,et al. Relation of CD4+CD25+ Regulatory T-Cell Suppression of Allergen-Driven T-Cell Activation to Atopic Status and Expression of Allergic Disease , 2005, Pediatrics.
[15] D Norbäck,et al. Current asthma and respiratory symptoms among pupils in relation to dietary factors and allergens in the school environment. , 2005, Indoor air.
[16] A. Rudin,et al. Defective suppression of Th2 cytokines by CD4+CD25+ regulatory T cells in birch allergics during birch pollen season , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[17] P. Alzari,et al. cDNA Cloning and Sequencing Reveal the Major Horse Allergen Equ c1 to Be a Glycoprotein Member of the Lipocalin Superfamily* , 1996, The Journal of Biological Chemistry.
[18] J. Ceuppens,et al. Allergen‐specific T cells from birch‐pollen‐allergic patients and healthy controls differ in T helper 2 cytokine and in interleukin‐10 production , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[19] F. Spertini,et al. Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. , 1997, The Journal of allergy and clinical immunology.
[20] R. Garman,et al. Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. , 1996, The Journal of allergy and clinical immunology.
[21] Philippa Marrack,et al. T cells down-modulate peptide-MHC complexes on APCs in vivo , 2002, Nature Immunology.
[22] J. Pelkonen,et al. Complementary DNA cloning of the predominant allergen of bovine dander: a new member in the lipocalin family. , 1996, The Journal of allergy and clinical immunology.
[23] D R Flower,et al. Lipocalins: unity in diversity. , 2000, Biochimica et biophysica acta.
[24] Dominique Charron,et al. HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy , 2000, The Journal of Immunology.
[25] H. Breiteneder,et al. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. , 1998, The Journal of allergy and clinical immunology.
[26] A. Närvänen,et al. Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells. , 2005, International immunology.
[27] P. Cullinan,et al. Determination of the T cell epitopes of the lipocalin allergen, Rat n 1 , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[28] R. Simon,et al. Redundancy in Antigen-Presenting Function of the HLA-DR and -DQ Molecules in the Multiple Sclerosis-Associated HLA-DR2 Haplotype1 , 2006, The Journal of Immunology.
[29] G. Roberts,et al. Horse allergy in children , 2000, BMJ : British Medical Journal.
[30] B. Maillère,et al. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. , 2003, European journal of immunology.
[31] Roberto Mallone,et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. , 2004, Diabetes.
[32] T. Virtanen,et al. Mammalian allergens. , 2004, Clinical allergy and immunology.
[33] S. Auriola,et al. Assessment of recombinant dog allergens Can f 1 and Can f 2 for the diagnosis of dog allergy , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[34] J. Drijfhout,et al. HLA-DR binding analysis of peptides from islet antigens in IDDM. , 1998, Diabetes.
[35] A. Rees,et al. Properties of HLA class II molecules divergently associated with Goodpasture's disease. , 2000, International immunology.
[36] A. Ménez,et al. Complementarity and redundancy of the binding specificity of HLA‐DRB1, ‐DRB3, ‐DRB4 and ‐DRB5 molecules , 2001, European journal of immunology.
[37] D. Wraith,et al. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. , 1996, Immunology today.
[38] J. Rouvinen,et al. Molecular and crystal properties of Bos d 2, an allergenic protein of the lipocalin family. , 1998, Biochemical and biophysical research communications.
[39] R. Mäntyjärvi,et al. Allergy to lipocalins: a consequence of misguided T-cell recognition of self and nonself? , 1999, Immunology today.
[40] E. Appella,et al. Mechanisms influencing the immunodominance of T cell determinants , 1988, The Journal of experimental medicine.
[41] D. Umetsu,et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. , 1999, Clinical immunology.
[42] H. Reijonen,et al. Low‐avidity recognition by CD4+ T cells directed to self‐antigens , 2003, European journal of immunology.
[43] M. Dallman,et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease , 2004, The Lancet.
[44] Alain Sanson,et al. HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity1 , 2002, The Journal of Immunology.